Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTSO NASDAQ:NMTC NASDAQ:SINT NASDAQ:STRR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.60-0.9%$0.65$0.50▼$1.39$37.87M1.4378,491 shs27,541 shsNMTCNeuroOne Medical Technologies$4.56+0.3%$4.53$3.27▼$6.96$38.36M0.643,673 shs10,920 shsSINTSintx Technologies$2.48+3.7%$2.62$1.99▼$6.78$10.21M0.6135,910 shs1,797 shsSTRRStar Equity$9.38+1.4%$9.74$8.26▼$11.99$34.78M0.432,838 shs2,122 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents+6.93%-0.08%-0.07%-9.30%-30.97%NMTCNeuroOne Medical Technologies+5.58%-3.40%-8.80%-3.03%+15.95%SINTSintx Technologies-0.42%+13.27%-10.15%-18.71%-4.40%STRRStar Equity+1.22%-1.44%-0.16%-4.18%+304.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.60-0.9%$0.65$0.50▼$1.39$37.87M1.4378,491 shs27,541 shsNMTCNeuroOne Medical Technologies$4.56+0.3%$4.53$3.27▼$6.96$38.36M0.643,673 shs10,920 shsSINTSintx Technologies$2.48+3.7%$2.62$1.99▼$6.78$10.21M0.6135,910 shs1,797 shsSTRRStar Equity$9.38+1.4%$9.74$8.26▼$11.99$34.78M0.432,838 shs2,122 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents+6.93%-0.08%-0.07%-9.30%-30.97%NMTCNeuroOne Medical Technologies+5.58%-3.40%-8.80%-3.03%+15.95%SINTSintx Technologies-0.42%+13.27%-10.15%-18.71%-4.40%STRRStar Equity+1.22%-1.44%-0.16%-4.18%+304.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTSOCytosorbents 2.00Hold$5.38789.90% UpsideNMTCNeuroOne Medical Technologies 2.25Hold$13.50196.38% UpsideSINTSintx Technologies 2.33Hold$11.00343.73% UpsideSTRRStar Equity 2.40Hold$16.5076.00% UpsideCurrent Analyst Ratings BreakdownLatest SINT, CTSO, NMTC, and STRR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026STRRStar Equity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026SINTSintx Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/13/2026SINTSintx Technologies HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.004/8/2026CTSOCytosorbents Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026SINTSintx Technologies Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $12.003/26/2026CTSOCytosorbents D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/23/2026STRRStar Equity Litchfield Hills ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$21.00 ➝ $28.003/13/2026NMTCNeuroOne Medical Technologies Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/9/2026STRRStar Equity Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/4/2026STRRStar Equity Noble FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/2/2026NMTCNeuroOne Medical Technologies JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTSOCytosorbents$37.06M1.02N/AN/A$0.09 per share6.71NMTCNeuroOne Medical Technologies$8.72M4.40N/AN/A$0.85 per share5.36SINTSintx Technologies$1.02M10.01N/AN/A$0.80 per share3.10STRRStar Equity$172.16M0.20$0.63 per share14.84$19.12 per share0.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTSOCytosorbents-$8.20M-$0.13N/AN/AN/A-22.12%-150.53%-32.75%5/13/2026 (Estimated)NMTCNeuroOne Medical Technologies-$3.61M-$1.02N/AN/AN/A-78.34%-119.92%-78.86%5/12/2026 (Estimated)SINTSintx Technologies-$10.36M-$5.66N/AN/AN/A-1,018.08%-242.76%-99.86%5/15/2026 (Estimated)STRRStar Equity-$5.92M-$2.05N/A6.94N/A-3.44%-1.17%-0.73%5/12/2026 (Estimated)Latest SINT, CTSO, NMTC, and STRR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026N/ASINTSintx Technologies-$0.66N/AN/AN/A$0.30 millionN/A5/13/2026Q1 2026CTSOCytosorbents-$0.06N/AN/AN/A$9.40 millionN/A5/12/2026Q2 2026NMTCNeuroOne Medical Technologies-$0.2267N/AN/AN/A$2.58 millionN/A5/12/2026N/ASTRRStar Equity$0.05N/AN/AN/A$52.57 millionN/A3/25/2026Q4 2025CTSOCytosorbents-$0.05-$0.09-$0.04-$0.09$9.22 million$9.23 million3/17/2026Q4 2025STRRStar Equity$0.13-$0.10-$0.23-$0.67$59.08 million$56.79 million2/17/2026Q1 2026NMTCNeuroOne Medical Technologies-$0.24-$0.18+$0.06-$0.03$2.47 million$2.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTSOCytosorbentsN/AN/AN/AN/AN/ANMTCNeuroOne Medical TechnologiesN/AN/AN/AN/AN/ASINTSintx TechnologiesN/AN/AN/AN/AN/ASTRRStar EquityN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTSOCytosorbents2.822.131.58NMTCNeuroOne Medical TechnologiesN/A6.415.09SINTSintx TechnologiesN/A1.511.29STRRStar Equity0.092.101.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTSOCytosorbents32.87%NMTCNeuroOne Medical Technologies16.07%SINTSintx Technologies18.38%STRRStar Equity3.84%Insider OwnershipCompanyInsider OwnershipCTSOCytosorbents7.30%NMTCNeuroOne Medical Technologies11.80%SINTSintx Technologies4.08%STRRStar Equity33.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTSOCytosorbents22062.70 million58.12 millionOptionableNMTCNeuroOne Medical Technologies208.42 million7.43 millionOptionableSINTSintx Technologies404.12 million3.95 millionNot OptionableSTRRStar Equity1,2003.71 million2.47 millionNot OptionableSINT, CTSO, NMTC, and STRR HeadlinesRecent News About These CompaniesStar Equity Holdings to Release First Quarter 2026 Financial Results on May 11May 6 at 4:15 PM | globenewswire.comStar Equity Holdings Announces Proposal to Acquire GEE Group for $0.30 per ShareMay 6 at 8:30 AM | globenewswire.comStar Equity Fund Calls on GEE Group to Change Egregious Executive Employment AgreementsApril 29, 2026 | globenewswire.comStar Equity Holdings, Inc.April 12, 2026 | edition.cnn.comInsider Selling: Star Equity (NASDAQ:STRR) CEO Sells 7,722 Shares of StockApril 3, 2026 | insidertrades.comStar Equity (NASDAQ:STRR) Director Louis Parks Acquires 1,500 SharesMarch 29, 2026 | insidertrades.comStar Equity Holdings (STRR) price target increased by 11.76% to 19.38March 27, 2026 | msn.comLooking for a Growth Stock? 3 Reasons Why Star Equity Holdings (STRR) is a Solid ChoiceMarch 25, 2026 | zacks.comWall Street Analysts Believe Star Equity Holdings (STRR) Could Rally 92.31%: Here's is How to TradeMarch 25, 2026 | zacks.comStar Equity Holdings, Inc.: Star Equity Holdings Reports 2025 Fourth Quarter and Full-Year ResultsMarch 21, 2026 | finanznachrichten.deStar Equity Holdings Inc (STRR) Q4 2025 Earnings Call Highlights: Impressive Revenue and Profit ...March 19, 2026 | uk.finance.yahoo.comStar Equity outlines 2026 growth plans with Building Solutions and Energy Services poised for recoveryMarch 18, 2026 | seekingalpha.comStar Equity Holdings, Inc. (STRR) Q4 2025 Earnings Call TranscriptMarch 18, 2026 | seekingalpha.comStar Equity Holdings: Q4 Earnings SnapshotMarch 17, 2026 | myjournalcourier.comMStar Equity Holdings (STRR) Reports Q4 Loss, Lags Revenue EstimatesMarch 17, 2026 | zacks.comStar Equity Holdings Reports 2025 Fourth Quarter and Full-Year ResultsMarch 17, 2026 | globenewswire.comStar Equity Holdings to Release Fourth Quarter 2025 Financial Results on March 17March 13, 2026 | globenewswire.comStar Equity Holdings (STRR) to Report Q4 Results: Wall Street Expects Earnings GrowthMarch 6, 2026 | zacks.comStar Equity Holdings, Inc. Declares Cash Dividend of $0.25 Per Share of 10% Series A Cumulative Perpetual Preferred StockFebruary 13, 2026 | globenewswire.comGEE Group Addresses Star Equity’s Public Commentary Regarding Indication of InterestJanuary 31, 2026 | palmbeachpost.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSINT, CTSO, NMTC, and STRR Company DescriptionsCytosorbents NASDAQ:CTSO$0.60 -0.01 (-0.90%) As of 10:55 AM Eastern This is a fair market value price provided by Massive. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.NeuroOne Medical Technologies NASDAQ:NMTC$4.56 +0.02 (+0.33%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.Sintx Technologies NASDAQ:SINT$2.48 +0.09 (+3.72%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.Star Equity NASDAQ:STRR$9.38 +0.13 (+1.35%) As of 10:58 AM Eastern This is a fair market value price provided by Massive. Learn more.Star Equity Holdings, Inc. engages in the construction business in the United States and internationally. It operates through two segments: Construction, and Investments. It manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; holds real estate assets; and manages investments. The company was formerly known as Digirad Corporation and changed its name to Star Equity Holdings, Inc. in December 2020. Star Equity Holdings, Inc. was founded in 1985 and is headquartered in Old Greenwich, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
